Choose from over 300 knock-in and knockout cell line models in many standard cancer cell lines such as DLD1, MCF10A, and HCT116.
Cancer-related cell lines
1Start Here
2Choose
Recapitulate disease phenotypes
Endogenous knock-in cell lines enable a clear understanding of a gene or mutation’s contribution to a phenotype including conditional knockouts to model human disease
Confirm your results
We provide truly isogenic cell line pairs. Each cell model comes with the parental cell line as an additional control
Knockout and knock-in models
Our knock in models have more complex genetic modifications such as:
insertions
base pair changes
deletions
truncations
FLAG-tagged proteins for purification
Limited use agreement
All cell lines engineered by Horizon Discovery are purchased under the terms of our Limited Use Label License.
We are confident that HAP1 and Cancer-related Ready-to-go cell lines are the ideal product to further your research
However, if you are not satisfied with the performance of any of our HAP1 and Cancer-related Ready-to-go cell lines, please contact us at technical@horizondiscovery.com and we will work diligently with you to resolve any problems, as detailed in our terms and conditions of sales.
Products that have utilized CRISPR Cas9 systems and methodologies to knock-in a gene, and their use, may be the subject of one or more of the following patents and applications controlled by Sigma-Aldrich Co. LLC (SIGMA): Patent applications and issued patents that entered their respective National Stage from PCT International Pub. No. WO 2014/089290, including, but not limited to, the following, and substitutions, divisions, continuations, continuations-in-part, reissues, re-examinations, and extensions thereof: Australia Patent Nos. 2013355214; 2017204031; and 2018229489; Canada Patent Nos. 2,891,347 and 2,977,152; China Patent No. CN105142669; European Patent Nos. EP 2 928 496 B1; EP 3 138 910 B1, 3 138 911 B1, EP 3 138 912 B1, EP 3 360 964 B1, EP 3 363 902 B1; Israel Patent No. IL238856; Singapore Patent No. 11201503824S; South Korea Patent Nos. 10-1844123 and 10-2006880; and U.S. Patent Nos. 10,731,181 and 10,745,716; and U.S. Application Serial Nos. 15/188,927; 15/188,931; and 15/456,204 (the “Patent Rights”).
